---
title: "Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co., Ltd. (300937.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300937.SZ.md"
symbol: "300937.SZ"
name: "Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co., Ltd."
industry: "Drug Retail"
datetime: "2026-05-20T08:34:48.567Z"
locales:
  - [en](https://longbridge.com/en/quote/300937.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300937.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300937.SZ.md)
---

# Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co., Ltd. (300937.SZ)

## Company Overview

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. provides omni-channel pharmaceutical distribution services in China. It is involved in pharmaceutical B2B e-commerce, production, wholesale, and retail businesses, as well as provides logistics services. It offers Western medicine, Chinese patent medicine, Chinese herbal medicine slices and Chinese medicinal materials, food and health food, medical devices and non-pharmaceuticals, and other categories.

| Item | Detail |
|------|--------|
| Industry | Drug Retail |
| Exchange | CN Market |
| Website | [www.hezongyy.com](https://www.hezongyy.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.53)**

**Industry**: Drug Retail

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 8 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3.49% |  |
| Net Profit YoY | -274.57% |  |
| P/B Ratio | 3.05 |  |
| Dividend Ratio | 0.38% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2496549808.47 |  |
| Revenue | 4438187665.30 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -2.36% | D |
| Profit Margin | -0.45% | D |
| Gross Margin | 10.15% | E |
| Revenue YoY | 3.49% | C |
| Net Profit YoY | -274.57% | E |
| Total Assets YoY | 8.66% | B |
| Net Assets YoY | -4.83% | D |
| Cash Flow Margin | -139.44% | E |
| OCF YoY | 3.49% | C |
| Turnover | 2.44 | A |
| Gearing Ratio | 57.62% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sichuan Hezong Medicine Easy-To-Buy Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3.49%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-274.57%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.05",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.38%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "2496549808.47",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4438187665.30",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-2.36%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-0.45%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "10.15%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "3.49%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-274.57%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.66%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-4.83%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-139.44%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "3.49%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "2.44",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "57.62%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -126.15 | 9/8 | 252.60 | 242.88 | 236.87 |
| PB | 3.05 | 8/8 | 3.89 | 3.39 | 3.18 |
| PS (TTM) | 0.56 | 5/8 | 0.74 | 0.66 | 0.61 |
| Dividend Yield | 0.38% | 8/8 | 0.36% | 0.34% | 0.30% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Yifeng Pharmacy (603939.SH) | B | C | B | C | C | B |
| 02 | DSL (603233.SH) | B | C | A | D | B | B |
| 03 | Huaren Health (301408.SZ) | B | B | A | D | A | B |
| 04 | SYPM (301017.SZ) | C | B | A | E | A | B |
| 05 | NO.1 PHARMACY (600833.SH) | C | C | A | C | C | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300937.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300937.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300937.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300937.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**